<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id>
<journal-id journal-id-type="publisher-id">ijms</journal-id>
<journal-title-group>
<journal-title>International Journal of Molecular Sciences</journal-title>
</journal-title-group>
<issn pub-type="epub">1422-0067</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30744146</article-id>
<article-id pub-id-type="pmc">6386932</article-id>
<article-id pub-id-type="doi">10.3390/ijms20030737</article-id>
<article-id pub-id-type="publisher-id">ijms-20-00737</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Histamine <italic>N</italic>-Methyltransferase in the Brain</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7056-6021</contrib-id>
<name>
<surname>Yoshikawa</surname>
<given-names>Takeo</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-20-00737">1</xref>
<xref ref-type="corresp" rid="c1-ijms-20-00737">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nakamura</surname>
<given-names>Tadaho</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-20-00737">1</xref>
<xref ref-type="aff" rid="af2-ijms-20-00737">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9068-7907</contrib-id>
<name>
<surname>Yanai</surname>
<given-names>Kazuhiko</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-20-00737">1</xref>
</contrib>
</contrib-group>
<aff id="af1-ijms-20-00737"><label>1</label>Department of Pharmacology, Tohoku University Graduate School of Medicine, 2-1, Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan; <email>tadaho@med.tohoku.ac.jp</email> (T.N.); <email>yanai@med.tohoku.ac.jp</email> (K.Y.)</aff>
<aff id="af2-ijms-20-00737"><label>2</label>Division of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, 1-15-1, Fukumuro, Miyagino-ku, Sendai 983-8536, Japan</aff>
<author-notes>
<corresp id="c1-ijms-20-00737"><label>*</label>Correspondence: <email>tyoshikawa@med.tohoku.ac.jp</email>; Tel.: +81-22-717-8058; Fax: +81-22-717-8060</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>10</day>
<month>2</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>2</month>
<year>2019</year>
</pub-date>
<volume>20</volume>
<issue>3</issue>
<elocation-id>737</elocation-id>
<history>
<date date-type="received">
<day>24</day>
<month>1</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>08</day>
<month>2</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 by the authors.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Brain histamine is a neurotransmitter and regulates diverse physiological functions. Previous studies have shown the involvement of histamine depletion in several neurological disorders, indicating the importance of drug development targeting the brain histamine system. Histamine <italic>N</italic>-methyltransferase (HNMT) is a histamine-metabolising enzyme expressed in the brain. Although pharmacological studies using HNMT inhibitors have been conducted to reveal the direct involvement of HNMT in brain functions, HNMT inhibitors with high specificity and sufficient blood–brain barrier permeability have not been available until now. Recently, we have phenotyped <italic>Hnmt</italic>-deficient mice to elucidate the importance of HNMT in the central nervous system. <italic>Hnmt</italic> disruption resulted in a robust increase in brain histamine concentration, demonstrating the essential role of HNMT in the brain histamine system. Clinical studies have suggested that single nucleotide polymorphisms of the human <italic>HNMT</italic> gene are associated with several brain disorders such as Parkinson’s disease and attention deficit hyperactivity disorder. Postmortem studies also have indicated that HNMT expression is altered in human brain diseases. These findings emphasise that an increase in brain histamine levels by novel HNMT inhibitors could contribute to the improvement of brain disorders.</p>
</abstract>
<kwd-group>
<kwd>diamine oxidase</kwd>
<kwd>histamine</kwd>
<kwd>histamine H<sub>3</sub> receptor</kwd>
<kwd>histamine <italic>N</italic>-methyltransferase</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-ijms-20-00737" sec-type="intro">
<title>1. Introduction</title>
<p>Histamine (2-[4-imidazolyl]ethylamine) was discovered by Sir Henry Hallet Dale and Sir Patrick Playfair Laidlaw in 1910 [<xref ref-type="bibr" rid="B1-ijms-20-00737">1</xref>]. Histamine mediates a wide variety of events such as allergic reactions, gastric acid secretion, and smooth muscle contraction through interaction with four histamine receptor subtypes (H<sub>1</sub>R–H<sub>4</sub>R). Pharmacological research targeting histamine action in peripheral organs has led to the development of drugs such as H<sub>1</sub>R antagonists for allergic diseases and H<sub>2</sub>R antagonists for gastric ulcers. This amine also acts as a neurotransmitter in the brain [<xref ref-type="bibr" rid="B2-ijms-20-00737">2</xref>]. Histaminergic neurons are located in the tuberomammillary nucleus of the hypothalamus and project their axons into various brain regions including the cerebral cortex, hypothalamus, basal ganglia, and amygdala [<xref ref-type="bibr" rid="B3-ijms-20-00737">3</xref>]. The number of histamine-producing neurons in the human brain is estimated to be approximately 64,000. Brain histamine regulates diverse physiological functions such as sleep–wake cycles, stress response, appetite, and memory. Extensive investigations have shown the pathophysiological involvement of the histaminergic nervous system in various neuropsychiatric disorders. A loss-of-function mutation of the <italic>histidine decarboxylase</italic> (<italic>HDC</italic>) gene (EC 4.1.1.22), the essential enzyme for histamine production, is associated with Tourette’s syndrome [<xref ref-type="bibr" rid="B4-ijms-20-00737">4</xref>]. Pathological changes in histamine neurons are involved in cognitive impairment [<xref ref-type="bibr" rid="B5-ijms-20-00737">5</xref>,<xref ref-type="bibr" rid="B6-ijms-20-00737">6</xref>,<xref ref-type="bibr" rid="B7-ijms-20-00737">7</xref>]. The reduction in histamine concentration in the cerebrospinal fluid was observed in narcolepsy patients [<xref ref-type="bibr" rid="B8-ijms-20-00737">8</xref>,<xref ref-type="bibr" rid="B9-ijms-20-00737">9</xref>,<xref ref-type="bibr" rid="B10-ijms-20-00737">10</xref>]. H<sub>1</sub>R binding potential was found to be decreased in patients with depression and schizophrenia (SCZ) via positron emission tomography [<xref ref-type="bibr" rid="B11-ijms-20-00737">11</xref>,<xref ref-type="bibr" rid="B12-ijms-20-00737">12</xref>]. This evidence suggests that the dysfunction of the histaminergic nervous system could play a causative role in various neurological disorders and that the increase in brain histamine might have therapeutic potential.</p>
<p>Over the past few decades, H<sub>3</sub>R receptors in the brain have attracted attention as therapeutic targets to modulate the histamine system. This receptor identified by Arrang et al. in 1983 is a Gi/o protein-coupled receptor and negatively regulates histamine release as a presynaptic autoreceptor at nerve end terminals [<xref ref-type="bibr" rid="B2-ijms-20-00737">2</xref>,<xref ref-type="bibr" rid="B13-ijms-20-00737">13</xref>]. H<sub>3</sub>R inverse agonists, which could induce histamine release, were developed by many pharmaceutical companies and were examined for their therapeutic effects on animal models for neurological disorders and also on patients suffering from brain diseases [<xref ref-type="bibr" rid="B14-ijms-20-00737">14</xref>,<xref ref-type="bibr" rid="B15-ijms-20-00737">15</xref>]. Although the beneficial effect of most H<sub>3</sub>R inverse agonists is inconclusive, pitolisant, an H<sub>3</sub>R antagonist developed by Schwartz et al. [<xref ref-type="bibr" rid="B16-ijms-20-00737">16</xref>], was approved for the treatment of narcolepsy by the European Medical Agency in 2016 [<xref ref-type="bibr" rid="B17-ijms-20-00737">17</xref>], emphasising the involvement of histamine concentration in brain functions.</p>
<p>Neurotransmitter clearance is very important for maintaining normal neurotransmitter concentration. The neurotransmitters released into extracellular spaces are cleared by transporters and /or enzymes in the adjacent neurons or astrocytes to avoid excessive neuronal activation. Dysfunctional neurotransmitter clearance plays a causative role in various neurological disorders, including SCZ and depression. Indeed, various drugs, such as tricyclic antidepressants, serotonin norepinephrine re-uptake inhibitors, and monoamine oxidase inhibitors, block neurotransmitter clearance and exert their therapeutic actions in patients suffering from brain diseases. This evidence supports that histamine clearance machinery could be a therapeutic target for developing novel drugs that improve brain functions. However, the mechanism of brain histamine clearance had not been clarified.</p>
<p>Previous studies using rodents showed that astrocytes play an important role in histamine clearance [<xref ref-type="bibr" rid="B18-ijms-20-00737">18</xref>]. We recently investigated the molecular mechanism of histamine clearance using primary human astrocytes [<xref ref-type="bibr" rid="B19-ijms-20-00737">19</xref>]. Our in vitro experiments showed that human astrocytes transport histamine dominantly through plasma membrane monoamine transporter (PMAT) and also through organic cation transporter 3 (OCT3). Next, the histamine transported into the cytosol is metabolised by histamine <italic>N</italic>-methyltransferase (HNMT) (EC 2.1.1.8) (<xref ref-type="fig" rid="ijms-20-00737-f001">Figure 1</xref>). PMAT and OCT3, which are polyspecific transporters, transport various monoamines, including serotonin, dopamine, norepinephrine, and histamine [<xref ref-type="bibr" rid="B20-ijms-20-00737">20</xref>]. PMAT, which was identified in 2004, is widely distributed in the brain [<xref ref-type="bibr" rid="B21-ijms-20-00737">21</xref>,<xref ref-type="bibr" rid="B22-ijms-20-00737">22</xref>]. Several reports suggested that PMAT plays a role in serotonin clearance [<xref ref-type="bibr" rid="B23-ijms-20-00737">23</xref>,<xref ref-type="bibr" rid="B24-ijms-20-00737">24</xref>], and that mutations in the human <italic>PMAT</italic> genes coupled with low transport activity are related to autism spectrum disorders [<xref ref-type="bibr" rid="B25-ijms-20-00737">25</xref>], indicating the involvement of PMAT in brain monoamine concentration. However, <italic>Pmat</italic> deficiency in mice does not greatly affect brain histamine concentration under non-stressful conditions (our unpublished observation) nor induces behavioural abnormalities [<xref ref-type="bibr" rid="B26-ijms-20-00737">26</xref>]. OCT3 is expressed in different brain regions including the cerebral cortex, hippocampus, and cerebellum [<xref ref-type="bibr" rid="B27-ijms-20-00737">27</xref>]. The contribution of OCT3 to serotonin and dopamine concentrations has already been reported [<xref ref-type="bibr" rid="B28-ijms-20-00737">28</xref>,<xref ref-type="bibr" rid="B29-ijms-20-00737">29</xref>]. Zhu et al. examined the importance of OCT3 in brain histamine concentration [<xref ref-type="bibr" rid="B30-ijms-20-00737">30</xref>]. They showed that OCT3 is not involved in brain histamine concentration in normal conditions, whereas histamine content in the brain cortex is elevated in <italic>Oct3</italic>-deficient mice after cerebral ischemia. These results might indicate the minor contribution of these transporters to brain histamine concentration, although further studies are essential to examine the importance of PMAT and OCT3 in histamine clearance. In contrast, our recent study using <italic>Hnmt</italic> knockout mice clearly showed that Hnmt plays a predominant role in brain histamine concentration and the regulation of the histaminergic nervous system [<xref ref-type="bibr" rid="B31-ijms-20-00737">31</xref>]. In this article, we focus on HNMT function in the central nervous system (CNS).</p>
</sec>
<sec id="sec2-ijms-20-00737">
<title>2. Histamine-Metabolising Enzymes</title>
<p>There are two different enzymes for the inactivation of histamine: diamine oxidase (DAO) (EC 1.4.3.22) and HNMT. DAO, also known as histaminase, is the product of the <italic>AOC1</italic> gene. DAO acts as a homodimeric protein to oxidatively deaminate various amines including histamine, putrescine, and spermidine [<xref ref-type="bibr" rid="B35-ijms-20-00737">35</xref>,<xref ref-type="bibr" rid="B36-ijms-20-00737">36</xref>]. DAO is highly expressed in the digestive tract. The K<sub>m</sub> (Michaelis constant) value of human intestinal DAO to histamine was calculated as 19 µM [<xref ref-type="bibr" rid="B37-ijms-20-00737">37</xref>]. DAO plays a role in detoxification of dietary histamine to reduce histamine uptake through enterocytes. Thus, impaired DAO activity results in the increase of histamine absorption and the elevation of blood histamine concentration. Although DAO is also highly expressed in the kidneys and placenta, DAO expression in the CNS is low or absent [<xref ref-type="bibr" rid="B38-ijms-20-00737">38</xref>], indicating that DAO metabolises histamine in the peripheral organs but not the CNS.</p>
<p>HNMT is an enzyme catalysing the transfer of a methyl group from S-adenosyl-<sc>l</sc>-methionine (SAM) to histamine, yielding <italic>N<sup>τ</sup></italic>-methylhistamine and S-adenosyl-<sc>l</sc>-homocysteine (<xref ref-type="fig" rid="ijms-20-00737-f002">Figure 2</xref>). The human <italic>HNMT</italic> gene was cloned by Girard et al. in 1994 and encodes a 33 kDa protein consisting of 292 amino acids [<xref ref-type="bibr" rid="B39-ijms-20-00737">39</xref>] (<xref ref-type="table" rid="ijms-20-00737-t001">Table 1</xref>). Although HNMT is widely observed in vertebrates including humans, rodents, birds, lizards, and amphibians, the expression of HNMT has not been confirmed in invertebrates and plants. In mammals, HNMT is widely expressed in various organs including liver, kidney, and brain [<xref ref-type="bibr" rid="B40-ijms-20-00737">40</xref>]; and methylated histamine metabolites are abundantly excreted in urine [<xref ref-type="bibr" rid="B41-ijms-20-00737">41</xref>], suggesting the important role of HNMT in histamine metabolism. Brain HNMT activity in the CNS was first detected in the soluble supernatant fraction from guinea pig brain in 1959 [<xref ref-type="bibr" rid="B42-ijms-20-00737">42</xref>]. Schayer and Reilly confirmed the existence of methylated histamine inactivated by HNMT in guinea pig brain [<xref ref-type="bibr" rid="B43-ijms-20-00737">43</xref>]. Human HNMT activity has also been detected in the frontal, temporal, parietal, occipital, and cerebellar cortices [<xref ref-type="bibr" rid="B44-ijms-20-00737">44</xref>]. The Human Protein Atlas project showed a high expression of HNMT in the cerebellum and medium expression in the cerebral cortex, hippocampus, and caudate [<xref ref-type="bibr" rid="B45-ijms-20-00737">45</xref>]. The project also found that both neurons and glial cells express HNMT. An <italic>in situ</italic> hybridisation study in Allen Mouse Brain Atlas showed the highest mRNA expression of <italic>HNMT</italic> in the cortical subplate [<xref ref-type="bibr" rid="B46-ijms-20-00737">46</xref>]. Northern blot analysis using mouse and rat brains revealed ubiquitous expression of <italic>Hnmt</italic> except in rat cerebellum and mouse striatum [<xref ref-type="bibr" rid="B47-ijms-20-00737">47</xref>]. Immunohistochemical analysis using bovine brain revealed that several neurons including the oculomotor nucleus, red nucleus, facial nucleus, and dorsal vagal nucleus strongly express Hnmt [<xref ref-type="bibr" rid="B33-ijms-20-00737">33</xref>]. However, the detailed distribution of brain HNMT in mice, rats, and humans is still unknown. Further immunohistochemical analysis using specific antibodies is essential to understanding detailed HNMT distribution in the CNS.</p>
</sec>
<sec id="sec3-ijms-20-00737">
<title>3. HNMT and Human Brain Diseases</title>
<p>The effects of genetic polymorphism of human <italic>HNMT</italic> on enzymatic activity was first reported by Preuss et al. in 1998 [<xref ref-type="bibr" rid="B40-ijms-20-00737">40</xref>]. They showed that a C-to-T transition at nucleotide 314 (C314T) in exon 4 replaces threonine with isoleucine at codon 105 (Thr105Ile), leading to decreased enzymatic activity. Although amino acid residue 105 is distal from the substrate binding sites, the C314T polymorphism has a great impact on active site structure and dynamics, resulting in the increased K<sub>m</sub> value of human HNMT for histamine and SAM by 1.3- and 1.8-fold, respectively [<xref ref-type="bibr" rid="B52-ijms-20-00737">52</xref>,<xref ref-type="bibr" rid="B53-ijms-20-00737">53</xref>]. Several groups examined the association of C314T polymorphism with Parkinson’s disease (PD) [<xref ref-type="bibr" rid="B54-ijms-20-00737">54</xref>,<xref ref-type="bibr" rid="B55-ijms-20-00737">55</xref>,<xref ref-type="bibr" rid="B56-ijms-20-00737">56</xref>,<xref ref-type="bibr" rid="B57-ijms-20-00737">57</xref>], and the meta-analysis of these four studies suggested a protective role of this polymorphism against the development of PD [<xref ref-type="bibr" rid="B58-ijms-20-00737">58</xref>] (<xref ref-type="table" rid="ijms-20-00737-t002">Table 2</xref>). Other genetic association studies suggested the involvement of the C314T substitution in SCZ [<xref ref-type="bibr" rid="B57-ijms-20-00737">57</xref>], attention deficit hyperactivity disorder (ADHD) [<xref ref-type="bibr" rid="B59-ijms-20-00737">59</xref>] and migraine [<xref ref-type="bibr" rid="B60-ijms-20-00737">60</xref>] but not in Alzheimer’s disease (AD) [<xref ref-type="bibr" rid="B61-ijms-20-00737">61</xref>], amyotrophic lateral sclerosis [<xref ref-type="bibr" rid="B62-ijms-20-00737">62</xref>], multiple sclerosis [<xref ref-type="bibr" rid="B63-ijms-20-00737">63</xref>], or restless legs syndrome [<xref ref-type="bibr" rid="B64-ijms-20-00737">64</xref>]. The effect of the C314T polymorphism on alcoholism was inconclusive [<xref ref-type="bibr" rid="B65-ijms-20-00737">65</xref>,<xref ref-type="bibr" rid="B66-ijms-20-00737">66</xref>]. An A-to-G polymorphism at nucleotide 939 in the 3′ untranslated region of the human <italic>HNMT</italic> gene increases <italic>HNMT</italic> mRNA stability and increases HNMT protein, and enhances enzymatic activity [<xref ref-type="bibr" rid="B67-ijms-20-00737">67</xref>]. An A939G polymorphism is related to several brain disorders such as myasthenia gravis and ADHD [<xref ref-type="bibr" rid="B59-ijms-20-00737">59</xref>,<xref ref-type="bibr" rid="B68-ijms-20-00737">68</xref>]. Recently, Heidari et al. reported that two novel mutations in the human <italic>HNMT</italic> gene (G179A and T632C) impairs its enzymatic activity, leading to intellectual disability [<xref ref-type="bibr" rid="B69-ijms-20-00737">69</xref>,<xref ref-type="bibr" rid="B70-ijms-20-00737">70</xref>].</p>
<p>Several postmortem studies examined the alteration of HNMT expression in neurological disorders. HNMT expression was increased at the inferior frontal gyrus in Huntington’s disease [<xref ref-type="bibr" rid="B71-ijms-20-00737">71</xref>], at the substantia nigra and putamen in PD [<xref ref-type="bibr" rid="B72-ijms-20-00737">72</xref>], and at the frontal cortex in Pick’s disease [<xref ref-type="bibr" rid="B73-ijms-20-00737">73</xref>]. <italic>HNMT</italic> mRNA expression was also elevated in the prefrontal cortex of female AD patients [<xref ref-type="bibr" rid="B74-ijms-20-00737">74</xref>]. On the other hand, HNMT expression was reduced at the anterior cingulated cortex in depression [<xref ref-type="bibr" rid="B75-ijms-20-00737">75</xref>] and the frontal cortex in Down syndrome [<xref ref-type="bibr" rid="B73-ijms-20-00737">73</xref>]. Although these results indicate the possible involvement of HNMT functions in neuropsychiatric disorders, it is still unknown whether alterations in HNMT activity exert the causative role in disease progression, play a compensatory function for impaired brain functions, or is a secondary outcome accompanied by primary pathological change. Therefore, these associations should be validated in larger studies and possibly by prospective clinical studies in the near future.</p>
</sec>
<sec id="sec4-ijms-20-00737">
<title>4. Pharmacological Analysis Using HNMT Inhibitors</title>
<p>Duch and colleagues discovered that metoprine, a derivative of 2,4-diaminopyrimidine, inhibited HNMT activity with a Ki value of 100 nM [<xref ref-type="bibr" rid="B76-ijms-20-00737">76</xref>,<xref ref-type="bibr" rid="B77-ijms-20-00737">77</xref>]. Because metoprine can cross the blood–brain barrier (BBB) due to its hydrophobicity (logP = 2.82) and increase brain histamine concentration [<xref ref-type="bibr" rid="B78-ijms-20-00737">78</xref>], many researchers have used this inhibitor to investigate the role of HNMT in the CNS. Pharmacological studies using metoprine indicated that the activation of the histaminergic system in the CNS affects a wide variety of brain functions such as antinociception [<xref ref-type="bibr" rid="B79-ijms-20-00737">79</xref>], suppression of energy intake [<xref ref-type="bibr" rid="B80-ijms-20-00737">80</xref>], hyperglycaemic action [<xref ref-type="bibr" rid="B81-ijms-20-00737">81</xref>], improvement of cognitive function [<xref ref-type="bibr" rid="B82-ijms-20-00737">82</xref>], antiepileptic effect [<xref ref-type="bibr" rid="B83-ijms-20-00737">83</xref>,<xref ref-type="bibr" rid="B84-ijms-20-00737">84</xref>,<xref ref-type="bibr" rid="B85-ijms-20-00737">85</xref>], and attenuation of methamphetamine-induced behavioural abnormalities [<xref ref-type="bibr" rid="B86-ijms-20-00737">86</xref>]. However, metoprine can also inhibit mammalian dihydrofolate reductase (EC 1.5.1.3) and decrease cellular folate metabolism, resulting in the attenuation of cell growth [<xref ref-type="bibr" rid="B87-ijms-20-00737">87</xref>,<xref ref-type="bibr" rid="B88-ijms-20-00737">88</xref>]; therefore, it cannot be ruled out that the low specificity of metoprine affected the results. Another HNMT inhibitor, SKF91488, developed by Beaven et al. can specifically inhibit the enzymatic activity devoid of histamine receptor agonist activity [<xref ref-type="bibr" rid="B89-ijms-20-00737">89</xref>]. Unfortunately, due to the poor BBB permeability of SKF91488, the brain research using SKF91488 has been limited [<xref ref-type="bibr" rid="B90-ijms-20-00737">90</xref>,<xref ref-type="bibr" rid="B91-ijms-20-00737">91</xref>,<xref ref-type="bibr" rid="B92-ijms-20-00737">92</xref>]. Therefore, novel HNMT inhibitors with high specificity and sufficient BBB permeability are expected to accelerate to pharmacological research on brain HNMT. Properties of commercially available HNMT inhibitors are summarised in <xref ref-type="table" rid="ijms-20-00737-t003">Table 3</xref> and <xref ref-type="fig" rid="ijms-20-00737-f003">Figure 3</xref>.</p>
</sec>
<sec id="sec5-ijms-20-00737">
<title>5. Phenotyping of <italic>Hnmt</italic>-deficient Mice </title>
<p>Recently, we phenotyped <italic>Hnmt</italic>-knockout (KO) mice for a better understanding of the role played by HNMT in brain function [<xref ref-type="bibr" rid="B31-ijms-20-00737">31</xref>]. First, we showed that histamine content from the cortices, diencephalons, brainstems, and cerebella of KO mice was at least 5-fold higher than that of wild-type (WT) mice. Histamine concentration was consistently higher in whole brain homogenates from neonatal, adolescent, and adult KO mice compared with those of WT mice. Higher extraneuronal histamine concentration in KO mice was also confirmed by in vivo microdialysis assay. However, other monoamines and their metabolites were not changed in KO mouse brains. Histamine concentration in several organs such as the skin and stomach was not elevated. These results demonstrated that Hnmt affected extracellular and intracellular histamine concentration of mouse brains throughout development and adult life. Next, we performed comprehensive behavioural testing to investigate the impact of elevated histamine on mouse behaviours. Although KO mice did not show anxiety-like behaviours, depression-like behaviours, impaired memory, or impaired motor function, highly aggressive behaviours and decreased locomotor activity in home cages were observed in KO mice. High aggression in KO mice was attenuated by pre-treatment of H<sub>2</sub>R antagonist zolantidine but not by H<sub>1</sub>R antagonist pyrilamine, indicating that elevated histamine by <italic>Hnmt</italic> deficiency activated H<sub>2</sub>R, thereby driving aggressive behaviours in mice. The decreased locomotor activity in home cages suggested that the sleep–wake cycle was disrupted in KO mice, resulting in extended immobility during periods that should have been active. Sleep analysis with electroencephalography and electromyography showed prolonged wakefulness during the inactive period and compensatory sleep during the active period. The average wake bout duration was increased in KO mice during zeitgeber time (ZT) 0–6 compared to WT mice, although the total number of wake and sleep bouts was not changed by <italic>Hnmt</italic> deficiency. Pyrilamine injection at ZT0 normalised both the prolonged wakefulness during ZT0–6 and the decreased wakefulness during ZT12–18 in KO mice, indicating that excessive H<sub>1</sub>R activation disrupted the sleep–wake cycle in KO mice. These results demonstrated that HNMT played an essential role in regulating brain histamine concentration and accordingly controls aggression and sleep–wake cycles. In this study, we deleted whole body <italic>Hnmt</italic> to understand the histaminergic nervous system using conventional knockout technology. We could not rule out the possibility that alteration of peripheral organ function might have affected brain functions. Thus, focal disruption of <italic>Hnmt</italic> in adult mice using an adeno-associated virus vector should be utilised to determine brain regions responsible for the aggression and sleep–wake abnormalities. It is also of interest to examine the behavioural changes of KO mice under stressful conditions such as sleep deprivation and social defeat stress so that better understanding of the role of HNMT in psychiatric diseases can be gained. Moreover, the role of Hnmt in rodent models of neurodegenerative disorders including PD and AD should be examined because several clinical studies showed alteration of the histaminergic nervous system in these disorders. Further studies are essential to confirm and extend our findings in rodent models and, eventually, in humans.</p>
</sec>
<sec id="sec6-ijms-20-00737">
<title>6. Future Perspectives</title>
<p>As mentioned above, dysfunction of the histaminergic nervous system is associated with various neuropsychiatric disorders including narcolepsy, AD, Tourette’s syndrome, eating disorders, and depression. Animal experiments using H<sub>3</sub>R inverse agonists or HNMT inhibitors suggest the therapeutic effect of histamine elevation on brain function [<xref ref-type="bibr" rid="B96-ijms-20-00737">96</xref>]. Dietary intake of histidine, as a precursor of histamine, also improved memory functions via the histamine system in rodents (unpublished observation) and ameliorated feelings of fatigue in humans [<xref ref-type="bibr" rid="B97-ijms-20-00737">97</xref>]. The marked effect of HNMT on brain histamine concentration indicates the strong therapeutic potential of HNMT inhibitors against brain diseases. <italic>Hnmt</italic> disruption enhanced brain histamine levels by &gt;6-fold [<xref ref-type="bibr" rid="B31-ijms-20-00737">31</xref>], whereas the impact of H<sub>3</sub>R antagonists on brain histamine was quite weak (&lt;2-fold) [<xref ref-type="bibr" rid="B98-ijms-20-00737">98</xref>]. Injection of a H<sub>3</sub>R inverse agonist ciproxifan transiently increased histamine release in mouse brains; however, the reduced histamine release was observed 24 h after the injection, possibly due to the development of receptor hypersensitivity or endogenous histamine deletion [<xref ref-type="bibr" rid="B99-ijms-20-00737">99</xref>]. Theoretically, HNMT inhibitors do not induce histamine depletion. These results indicate that HNMT inhibitors might have some advantages over H<sub>3</sub>R inverse agonists. Nevertheless, HNMT inhibitors might increase peripheral tissue histamine levels and exacerbate histamine-related diseases such as allergic rhinitis, urticaria, and gastric ulcers, as HNMT is also expressed in peripheral tissues. Several reports have shown that C314T polymorphisms of the <italic>HNMT</italic> gene is not associated with allergic asthma and rhinitis [<xref ref-type="bibr" rid="B100-ijms-20-00737">100</xref>,<xref ref-type="bibr" rid="B101-ijms-20-00737">101</xref>,<xref ref-type="bibr" rid="B102-ijms-20-00737">102</xref>], although a case-control study in Poland indicated the association of this polymorphism with asthma [<xref ref-type="bibr" rid="B103-ijms-20-00737">103</xref>]. We confirmed that <italic>Hnmt</italic> disruption did not affect histamine concentration of the skin and stomach [<xref ref-type="bibr" rid="B31-ijms-20-00737">31</xref>]. Thus, adverse effects induced by HNMT inhibition in the peripheral tissues might be negligible, although we could not rule out the possibility that HNMT inhibitors might aggravate allergic rhinitis, skin diseases, and peptic ulcers. Taken together, it is intriguing to find novel HNMT inhibitors with high specificity and sufficient BBB permeability. We hope that prominent HNMT inhibitors will help many patients who suffer from brain diseases.</p>
</sec>
</body>
<back>
<notes>
<title>Author Contributions</title>
<p>Wrote the manuscript: T.Y., T.N. and K.Y.</p>
</notes>
<notes>
<title>Funding</title>
<p>This work was supported by a Grant-in-Aid for Scientific Research (A) (26253016) from the Japan Society for the Promotion of Science (JSPS) and by a Grant-in-Aid for Scientific Research (C) (18K06886), also from JSPS. We also acknowledge the support of the Nishinomiya Basic Research Fund, Japan and Takeda Science Foundation, Japan.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-ijms-20-00737">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dale</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Laidlaw</surname>
<given-names>P.P.</given-names>
</name>
</person-group>
<article-title>The physiological action of beta-iminazolylethylamine</article-title>
<source/>J. Physiol.
          <year>1910</year>
<volume>41</volume>
<fpage>318</fpage>
<lpage>344</lpage>
<pub-id pub-id-type="doi">10.1113/jphysiol.1910.sp001406</pub-id>
<pub-id pub-id-type="pmid">16993030</pub-id>
</element-citation>
</ref>
<ref id="B2-ijms-20-00737">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haas</surname>
<given-names>H.L.</given-names>
</name>
<name>
<surname>Sergeeva</surname>
<given-names>O.A.</given-names>
</name>
<name>
<surname>Selbach</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Histamine in the nervous system</article-title>
<source/>Physiol. Rev.
          <year>2008</year>
<volume>88</volume>
<fpage>1183</fpage>
<lpage>1241</lpage>
<pub-id pub-id-type="doi">10.1152/physrev.00043.2007</pub-id>
<pub-id pub-id-type="pmid">18626069</pub-id>
</element-citation>
</ref>
<ref id="B3-ijms-20-00737">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watanabe</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Taguchi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shiosaka</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kubota</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Terano</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tohyama</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wada</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Distribution of the histaminergic neuron system in the central nervous system of rats; a fluorescent immunohistochemical analysis with histidine decarboxylase as a marker</article-title>
<source/>Brain Res.
          <year>1984</year>
<volume>295</volume>
<fpage>13</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="doi">10.1016/0006-8993(84)90811-4</pub-id>
<pub-id pub-id-type="pmid">6713171</pub-id>
</element-citation>
</ref>
<ref id="B4-ijms-20-00737">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baldan</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Gallezot</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Pogorelov</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Rapanelli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Crowley</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Loring</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gorczyca</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Billingslea</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Histidine decarboxylase deficiency causes tourette syndrome: Parallel findings in humans and mice</article-title>
<source/>Neuron
          <year>2014</year>
<volume>81</volume>
<fpage>77</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2013.10.052</pub-id>
<pub-id pub-id-type="pmid">24411733</pub-id>
</element-citation>
</ref>
<ref id="B5-ijms-20-00737">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zlomuzica</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dere</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Binder</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>De Souza Silva</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Huston</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Dere</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Neuronal histamine and cognitive symptoms in Alzheimer’s disease</article-title>
<source/>Neuropharmacology
          <year>2016</year>
<volume>106</volume>
<fpage>135</fpage>
<lpage>145</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.05.007</pub-id>
<pub-id pub-id-type="pmid">26025658</pub-id>
</element-citation>
</ref>
<ref id="B6-ijms-20-00737">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mazurkiewicz-Kwilecki</surname>
<given-names>I.M.</given-names>
</name>
<name>
<surname>Nsonwah</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Changes in the regional brain histamine and histidine levels in postmortem brains of Alzheimer patients</article-title>
<source/>Can. J. Physiol. Pharmacol.
          <year>1989</year>
<volume>67</volume>
<fpage>75</fpage>
<lpage>78</lpage>
<pub-id pub-id-type="doi">10.1139/y89-013</pub-id>
<pub-id pub-id-type="pmid">2713757</pub-id>
</element-citation>
</ref>
<ref id="B7-ijms-20-00737">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Panula</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rinne</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kuokkanen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Eriksson</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Sallmen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kalimo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Relja</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Neuronal histamine deficit in Alzheimer’s disease</article-title>
<source/>Neuroscience
          <year>1998</year>
<volume>82</volume>
<fpage>993</fpage>
<lpage>997</lpage>
<pub-id pub-id-type="doi">10.1016/S0306-4522(97)00353-9</pub-id>
<pub-id pub-id-type="pmid">9466423</pub-id>
</element-citation>
</ref>
<ref id="B8-ijms-20-00737">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishino</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sakurai</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Nevsimalova</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yanai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mignot</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls</article-title>
<source/>Sleep
          <year>2009</year>
<volume>32</volume>
<fpage>175</fpage>
<lpage>180</lpage>
<pub-id pub-id-type="doi">10.1093/sleep/32.2.175</pub-id>
<pub-id pub-id-type="pmid">19238804</pub-id>
</element-citation>
</ref>
<ref id="B9-ijms-20-00737">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanbayashi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kodama</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kondo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Satoh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chiba</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nishino</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome</article-title>
<source/>Sleep
          <year>2009</year>
<volume>32</volume>
<fpage>181</fpage>
<lpage>187</lpage>
<pub-id pub-id-type="doi">10.1093/sleep/32.2.181</pub-id>
<pub-id pub-id-type="pmid">19238805</pub-id>
</element-citation>
</ref>
<ref id="B10-ijms-20-00737">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bassetti</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Baumann</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Dauvilliers</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Croyal</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Robert</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Cerebrospinal fluid histamine levels are decreased in patients with narcolepsy and excessive daytime sleepiness of other origin</article-title>
<source/>J. Sleep Res.
          <year>2010</year>
<volume>19</volume>
<fpage>620</fpage>
<lpage>623</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2869.2010.00819.x</pub-id>
<pub-id pub-id-type="pmid">20846244</pub-id>
</element-citation>
</ref>
<ref id="B11-ijms-20-00737">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iwabuchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tashiro</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Itoh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Iwata</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Matsuoka</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yanai</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Histamine H1 receptors in schizophrenic patients measured by positron emission tomography</article-title>
<source/>Eur. Neuropsychopharmacol.
          <year>2005</year>
<volume>15</volume>
<fpage>185</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="doi">10.1016/j.euroneuro.2004.10.001</pub-id>
<pub-id pub-id-type="pmid">15695063</pub-id>
</element-citation>
</ref>
<ref id="B12-ijms-20-00737">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fukudo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tashiro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Utsumi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tamura</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Itoh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Iwata</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tashiro</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mochizuki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Funaki</surname>
<given-names>Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Decreased histamine H1 receptor binding in the brain of depressed patients</article-title>
<source/>Eur. J. Neurosci.
          <year>2004</year>
<volume>20</volume>
<fpage>803</fpage>
<lpage>810</lpage>
<pub-id pub-id-type="doi">10.1111/j.1460-9568.2004.03540.x</pub-id>
<pub-id pub-id-type="pmid">15255990</pub-id>
</element-citation>
</ref>
<ref id="B13-ijms-20-00737">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arrang</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Garbarg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor</article-title>
<source/>Nature
          <year>1983</year>
<volume>302</volume>
<fpage>832</fpage>
<lpage>837</lpage>
<pub-id pub-id-type="doi">10.1038/302832a0</pub-id>
<pub-id pub-id-type="pmid">6188956</pub-id>
</element-citation>
</ref>
<ref id="B14-ijms-20-00737">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Passani</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Blandina</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Histamine receptors in the CNS as targets for therapeutic intervention</article-title>
<source/>Trends Pharmacol. Sci
          <year>2011</year>
<volume>32</volume>
<fpage>242</fpage>
<lpage>249</lpage>
<pub-id pub-id-type="doi">10.1016/j.tips.2011.01.003</pub-id>
<pub-id pub-id-type="pmid">21324537</pub-id>
</element-citation>
</ref>
<ref id="B15-ijms-20-00737">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leurs</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bakker</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Timmerman</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>de Esch</surname>
<given-names>I.J.</given-names>
</name>
</person-group>
<article-title>The histamine H3 receptor: From gene cloning to H3 receptor drugs</article-title>
<source/>Nat. Rev. Drug Discov.
          <year>2005</year>
<volume>4</volume>
<fpage>107</fpage>
<lpage>120</lpage>
<pub-id pub-id-type="doi">10.1038/nrd1631</pub-id>
<pub-id pub-id-type="pmid">15665857</pub-id>
</element-citation>
</ref>
<ref id="B16-ijms-20-00737">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>The histamine H3 receptor: From discovery to clinical trials with pitolisant</article-title>
<source/>Br. J. Pharmacol.
          <year>2011</year>
<volume>163</volume>
<fpage>713</fpage>
<lpage>721</lpage>
<pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01286.x</pub-id>
<pub-id pub-id-type="pmid">21615387</pub-id>
</element-citation>
</ref>
<ref id="B17-ijms-20-00737">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Syed</surname>
<given-names>Y.Y.</given-names>
</name>
</person-group>
<article-title>Pitolisant: First Global Approval</article-title>
<source/>Drugs
          <year>2016</year>
<volume>76</volume>
<fpage>1313</fpage>
<lpage>1318</lpage>
<pub-id pub-id-type="doi">10.1007/s40265-016-0620-1</pub-id>
<pub-id pub-id-type="pmid">27438291</pub-id>
</element-citation>
</ref>
<ref id="B18-ijms-20-00737">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huszti</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Histamine uptake into non-neuronal brain cells</article-title>
<source/>Inflamm. Res.
          <year>2003</year>
<volume>52</volume>
<fpage>S3</fpage>
<lpage>S6</lpage>
<pub-id pub-id-type="doi">10.1007/s000110300028</pub-id>
</element-citation>
</ref>
<ref id="B19-ijms-20-00737">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshikawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Naganuma</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Iida</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Harada</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mohsen</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Kasajima</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sasano</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yanai</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Molecular mechanism of histamine clearance by primary human astrocytes</article-title>
<source/>Glia
          <year>2013</year>
<volume>61</volume>
<fpage>905</fpage>
<lpage>916</lpage>
<pub-id pub-id-type="doi">10.1002/glia.22484</pub-id>
<pub-id pub-id-type="pmid">23505051</pub-id>
</element-citation>
</ref>
<ref id="B20-ijms-20-00737">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshikawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yanai</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Histamine Clearance Through Polyspecific Transporters in the Brain</article-title>
<source/>Handb. Exp. Pharmacol.
          <year>2017</year>
<volume>241</volume>
<fpage>173</fpage>
<lpage>187</lpage>
<pub-id pub-id-type="pmid">27679412</pub-id>
</element-citation>
</ref>
<ref id="B21-ijms-20-00737">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Engel</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Identification and characterization of a novel monoamine transporter in the human brain</article-title>
<source/>J. Biol. Chem.
          <year>2004</year>
<volume>279</volume>
<fpage>50042</fpage>
<lpage>50049</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M407913200</pub-id>
<pub-id pub-id-type="pmid">15448143</pub-id>
</element-citation>
</ref>
<ref id="B22-ijms-20-00737">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dahlin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hevner</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Expression and immunolocalization of the plasma membrane monoamine transporter in the brain</article-title>
<source/>Neuroscience
          <year>2007</year>
<volume>146</volume>
<fpage>1193</fpage>
<lpage>1211</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2007.01.072</pub-id>
<pub-id pub-id-type="pmid">17408864</pub-id>
</element-citation>
</ref>
<ref id="B23-ijms-20-00737">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daws</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Koek</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>N.C.</given-names>
</name>
</person-group>
<article-title>Revisiting serotonin reuptake inhibitors and the therapeutic potential of “uptake-2” in psychiatric disorders</article-title>
<source/>ACS Chem. Neurosci.
          <year>2013</year>
<volume>4</volume>
<fpage>16</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1021/cn3001872</pub-id>
<pub-id pub-id-type="pmid">23336039</pub-id>
</element-citation>
</ref>
<ref id="B24-ijms-20-00737">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matthaeus</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Schloss</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lau</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Differential Uptake Mechanisms of Fluorescent Substrates into Stem-Cell-Derived Serotonergic Neurons</article-title>
<source/>ACS Chem. Neurosci.
          <year>2015</year>
<volume>6</volume>
<fpage>1906</fpage>
<lpage>1912</lpage>
<pub-id pub-id-type="doi">10.1021/acschemneuro.5b00219</pub-id>
<pub-id pub-id-type="pmid">26503837</pub-id>
</element-citation>
</ref>
<ref id="B25-ijms-20-00737">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adamsen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ramaekers</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>H.T.</given-names>
</name>
<name>
<surname>Britschgi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rufenacht</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Meili</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bobrowski</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Philippe</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nava</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Van Maldergem</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene</article-title>
<source/>Mol. Autism.
          <year>2014</year>
<volume>5</volume>
<fpage>43</fpage>
<pub-id pub-id-type="doi">10.1186/2040-2392-5-43</pub-id>
<pub-id pub-id-type="pmid">25802735</pub-id>
</element-citation>
</ref>
<ref id="B26-ijms-20-00737">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Impaired monoamine and organic cation uptake in choroid plexus in mice with targeted disruption of the plasma membrane monoamine transporter (Slc29a4) gene</article-title>
<source/>J. Biol. Chem.
          <year>2013</year>
<volume>288</volume>
<fpage>3535</fpage>
<lpage>3544</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M112.436972</pub-id>
<pub-id pub-id-type="pmid">23255610</pub-id>
</element-citation>
</ref>
<ref id="B27-ijms-20-00737">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Kekuda</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Fei</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Leibach</surname>
<given-names>F.H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Conway</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Ganapathy</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain</article-title>
<source/>J. Biol. Chem.
          <year>1998</year>
<volume>273</volume>
<fpage>32776</fpage>
<lpage>32786</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.273.49.32776</pub-id>
<pub-id pub-id-type="pmid">9830022</pub-id>
</element-citation>
</ref>
<ref id="B28-ijms-20-00737">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baganz</surname>
<given-names>N.L.</given-names>
</name>
<name>
<surname>Horton</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Calderon</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Owens</surname>
<given-names>W.A.</given-names>
</name>
<name>
<surname>Munn</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Watts</surname>
<given-names>L.T.</given-names>
</name>
<name>
<surname>Koldzic-Zivanovic</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Jeske</surname>
<given-names>N.A.</given-names>
</name>
<name>
<surname>Koek</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Toney</surname>
<given-names>G.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Organic cation transporter 3: Keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2008</year>
<volume>105</volume>
<fpage>18976</fpage>
<lpage>18981</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0800466105</pub-id>
<pub-id pub-id-type="pmid">19033200</pub-id>
</element-citation>
</ref>
<ref id="B29-ijms-20-00737">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cui</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Aras</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Christian</surname>
<given-names>W.V.</given-names>
</name>
<name>
<surname>Rappold</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Hatwar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Panza</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jackson-Lewis</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Javitch</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Ballatori</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Przedborski</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2009</year>
<volume>106</volume>
<fpage>8043</fpage>
<lpage>8048</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0900358106</pub-id>
<pub-id pub-id-type="pmid">19416912</pub-id>
</element-citation>
</ref>
<ref id="B30-ijms-20-00737">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hata</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ogasawara</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kameda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yamauchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Schinkel</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Maeyama</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sakanaka</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Targeted disruption of organic cation transporter 3 (Oct3) ameliorates ischemic brain damage through modulating histamine and regulatory T cells</article-title>
<source/>J. Cereb. Blood Flow Metab.
          <year>2012</year>
<volume>32</volume>
<fpage>1897</fpage>
<lpage>1908</lpage>
<pub-id pub-id-type="doi">10.1038/jcbfm.2012.92</pub-id>
<pub-id pub-id-type="pmid">22739622</pub-id>
</element-citation>
</ref>
<ref id="B31-ijms-20-00737">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naganuma</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yoshikawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Iida</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Miura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Karpati</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Matsuzawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yanai</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mogi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mochizuki</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Histamine <italic>N</italic>-methyltransferase regulates aggression and the sleep-wake cycle</article-title>
<source/>Sci. Rep.
          <year>2017</year>
<volume>7</volume>
<fpage>15899</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-16019-8</pub-id>
<pub-id pub-id-type="pmid">29162912</pub-id>
</element-citation>
</ref>
<ref id="B32-ijms-20-00737">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naganuma</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yoshikawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Iida</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Harada</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mohsen</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Miura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yanai</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Predominant role of plasma membrane monoamine transporters in monoamine transport in 1321N1, a human astrocytoma-derived cell line</article-title>
<source/>J. Neurochem.
          <year>2014</year>
<volume>129</volume>
<fpage>591</fpage>
<lpage>601</lpage>
<pub-id pub-id-type="doi">10.1111/jnc.12665</pub-id>
<pub-id pub-id-type="pmid">24471494</pub-id>
</element-citation>
</ref>
<ref id="B33-ijms-20-00737">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishibori</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tahara</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sawada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sakiyama</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nakaya</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Saeki</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Neuronal and vascular localization of histamine <italic>N</italic>-methyltransferase in the bovine central nervous system</article-title>
<source/>Eur. J. Neurosci.
          <year>2000</year>
<volume>12</volume>
<fpage>415</fpage>
<lpage>424</lpage>
<pub-id pub-id-type="doi">10.1046/j.1460-9568.2000.00914.x</pub-id>
<pub-id pub-id-type="pmid">10712622</pub-id>
</element-citation>
</ref>
<ref id="B34-ijms-20-00737">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakurai</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sakurai</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Oreland</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Nishiyama</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yanai</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Evidence for the presence of histamine uptake into the synaptosomes of rat brain</article-title>
<source/>Pharmacology
          <year>2006</year>
<volume>78</volume>
<fpage>72</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="doi">10.1159/000095637</pub-id>
<pub-id pub-id-type="pmid">16960463</pub-id>
</element-citation>
</ref>
<ref id="B35-ijms-20-00737">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maintz</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Novak</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Histamine and histamine intolerance</article-title>
<source/>Am. J. Clin. Nutr.
          <year>2007</year>
<volume>85</volume>
<fpage>1185</fpage>
<lpage>1196</lpage>
<pub-id pub-id-type="doi">10.1093/ajcn/85.5.1185</pub-id>
<pub-id pub-id-type="pmid">17490952</pub-id>
</element-citation>
</ref>
<ref id="B36-ijms-20-00737">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGrath</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Hilmer</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Collyer</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Shepard</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Elmore</surname>
<given-names>B.O.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Dooley</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Guss</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Structure and inhibition of human diamine oxidase</article-title>
<source/>Biochemistry
          <year>2009</year>
<volume>48</volume>
<fpage>9810</fpage>
<lpage>9822</lpage>
<pub-id pub-id-type="doi">10.1021/bi9014192</pub-id>
<pub-id pub-id-type="pmid">19764817</pub-id>
</element-citation>
</ref>
<ref id="B37-ijms-20-00737">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bieganski</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kusche</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lorenz</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hesterberg</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Stahlknecht</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Feussner</surname>
<given-names>K.D.</given-names>
</name>
</person-group>
<article-title>Distribution and properties of human intestinal diamine oxidase and its relevance for the histamine catabolism</article-title>
<source/>Biochim. Biophys. Acta
          <year>1983</year>
<volume>756</volume>
<fpage>196</fpage>
<lpage>203</lpage>
<pub-id pub-id-type="doi">10.1016/0304-4165(83)90092-2</pub-id>
<pub-id pub-id-type="pmid">6403048</pub-id>
</element-citation>
</ref>
<ref id="B38-ijms-20-00737">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elmore</surname>
<given-names>B.O.</given-names>
</name>
<name>
<surname>Bollinger</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Dooley</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>Human kidney diamine oxidase: Heterologous expression, purification, and characterization</article-title>
<source/>J. Biol. Inorg. Chem.
          <year>2002</year>
<volume>7</volume>
<fpage>565</fpage>
<lpage>579</lpage>
<pub-id pub-id-type="doi">10.1007/s00775-001-0331-1</pub-id>
<pub-id pub-id-type="pmid">12072962</pub-id>
</element-citation>
</ref>
<ref id="B39-ijms-20-00737">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girard</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Otterness</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>Honchel</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wieben</surname>
<given-names>E.D.</given-names>
</name>
<name>
<surname>Weinshilboum</surname>
<given-names>R.M.</given-names>
</name>
</person-group>
<article-title>Human histamine <italic>N</italic>-methyltransferase pharmacogenetics: Cloning and expression of kidney cDNA</article-title>
<source/>Mol. Pharmacol.
          <year>1994</year>
<volume>45</volume>
<fpage>461</fpage>
<lpage>468</lpage>
<pub-id pub-id-type="pmid">8145732</pub-id>
</element-citation>
</ref>
<ref id="B40-ijms-20-00737">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Preuss</surname>
<given-names>C.V.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>Szumlanski</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Raftogianis</surname>
<given-names>R.B.</given-names>
</name>
<name>
<surname>Otterness</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Girard</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Weinshilboum</surname>
<given-names>R.M.</given-names>
</name>
</person-group>
<article-title>Human histamine <italic>N</italic>-methyltransferase pharmacogenetics: Common genetic polymorphisms that alter activity</article-title>
<source/>Mol. Pharmacol.
          <year>1998</year>
<volume>53</volume>
<fpage>708</fpage>
<lpage>717</lpage>
<pub-id pub-id-type="doi">10.1124/mol.53.4.708</pub-id>
<pub-id pub-id-type="pmid">9547362</pub-id>
</element-citation>
</ref>
<ref id="B41-ijms-20-00737">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cooper</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Schayer</surname>
<given-names>R.W.</given-names>
</name>
</person-group>
<article-title>Metabolism of C14 histamine in man</article-title>
<source/>J. Appl. Physiol.
          <year>1956</year>
<volume>9</volume>
<fpage>481</fpage>
<lpage>483</lpage>
<pub-id pub-id-type="pmid">13376480</pub-id>
</element-citation>
</ref>
<ref id="B42-ijms-20-00737">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>D.D.</given-names>
</name>
<name>
<surname>Tomchick</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Axelrod</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The distribution and properties of a histamine-methylating enzyme</article-title>
<source/>J. Biol. Chem.
          <year>1959</year>
<volume>234</volume>
<fpage>2948</fpage>
<lpage>2950</lpage>
<pub-id pub-id-type="pmid">13804910</pub-id>
</element-citation>
</ref>
<ref id="B43-ijms-20-00737">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schayer</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Reilly</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Metabolism of 14C-histamine in brain</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>1973</year>
<volume>187</volume>
<fpage>34</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="pmid">4746331</pub-id>
</element-citation>
</ref>
<ref id="B44-ijms-20-00737">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pacifici</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Donatelli</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Giuliani</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Histamine <italic>N</italic>-methyl transferase: Inhibition by drugs</article-title>
<source/>Br. J. Clin. Pharmacol.
          <year>1992</year>
<volume>34</volume>
<fpage>322</fpage>
<lpage>327</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2125.1992.tb05637.x</pub-id>
<pub-id pub-id-type="pmid">1457266</pub-id>
</element-citation>
</ref>
<ref id="B45-ijms-20-00737">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uhlen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fagerberg</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hallstrom</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Lindskog</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Oksvold</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mardinoglu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sivertsson</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kampf</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sjostedt</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Asplund</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Proteomics. Tissue-based map of the human proteome</article-title>
<source/>Science
          <year>2015</year>
<volume>347</volume>
<fpage>1260419</fpage>
<pub-id pub-id-type="doi">10.1126/science.1260419</pub-id>
<pub-id pub-id-type="pmid">25613900</pub-id>
</element-citation>
</ref>
<ref id="B46-ijms-20-00737">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lein</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Hawrylycz</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Ao</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ayres</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bensinger</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bernard</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Boe</surname>
<given-names>A.F.</given-names>
</name>
<name>
<surname>Boguski</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Brockway</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Byrnes</surname>
<given-names>E.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide atlas of gene expression in the adult mouse brain</article-title>
<source/>Nature
          <year>2007</year>
<volume>445</volume>
<fpage>168</fpage>
<lpage>176</lpage>
<pub-id pub-id-type="doi">10.1038/nature05453</pub-id>
<pub-id pub-id-type="pmid">17151600</pub-id>
</element-citation>
</ref>
<ref id="B47-ijms-20-00737">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kitanaka</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kitanaka</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Oue</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tada</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Takemura</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Genomic structure of the rat and mouse histamine <italic>N</italic>-methyltransferase gene</article-title>
<source/>Jpn. J. Pharmacol.
          <year>2002</year>
<volume>88</volume>
<fpage>85</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.1254/jjp.88.85</pub-id>
<pub-id pub-id-type="pmid">11855681</pub-id>
</element-citation>
</ref>
<ref id="B48-ijms-20-00737">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamauchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sekizawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nakazawa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ohkawara</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Katayose</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ohtsu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tamura</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Shibahara</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Takemura</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Structure and function of human histamine <italic>N</italic>-methyltransferase: Critical enzyme in histamine metabolism in airway</article-title>
<source/>Am. J. Physiol.
          <year>1994</year>
<volume>267</volume>
<fpage>L342</fpage>
<lpage>L349</lpage>
<pub-id pub-id-type="doi">10.1152/ajplung.1994.267.3.L342</pub-id>
<pub-id pub-id-type="pmid">7943261</pub-id>
</element-citation>
</ref>
<ref id="B49-ijms-20-00737">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>McGuire</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kozak</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>U.J.</given-names>
</name>
<name>
<surname>Siciliano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Weinshilboum</surname>
<given-names>R.M.</given-names>
</name>
</person-group>
<article-title>Mouse histamine <italic>N</italic>-methyltransferase: cDNA cloning, expression, gene cloning and chromosomal localization</article-title>
<source/>Inflamm. Res.
          <year>2001</year>
<volume>50</volume>
<fpage>300</fpage>
<lpage>308</lpage>
<pub-id pub-id-type="doi">10.1007/PL00000248</pub-id>
<pub-id pub-id-type="pmid">11475331</pub-id>
</element-citation>
</ref>
<ref id="B50-ijms-20-00737">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takemura</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Taguchi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Imamura</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Mizuguchi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kuroda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fukui</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yamatodani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wada</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Histamine <italic>N</italic>-methyltransferase from rat kidney. Cloning, nucleotide sequence, and expression in <italic>Escherichia coli</italic> cells</article-title>
<source/>J. Biol. Chem.
          <year>1992</year>
<volume>267</volume>
<fpage>15687</fpage>
<lpage>15691</lpage>
<pub-id pub-id-type="pmid">1639806</pub-id>
</element-citation>
</ref>
<ref id="B51-ijms-20-00737">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kitanaka</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kitanaka</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tsujimura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kakihana</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Terada</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Takemura</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Guinea pig histamine <italic>N</italic>-methyltransferase: cDNA cloning and mRNA distribution</article-title>
<source/>Jpn. J. Pharmacol.
          <year>2001</year>
<volume>85</volume>
<fpage>105</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="doi">10.1254/jjp.85.105</pub-id>
<pub-id pub-id-type="pmid">11243563</pub-id>
</element-citation>
</ref>
<ref id="B52-ijms-20-00737">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horton</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Sawada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nishibori</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Two polymorphic forms of human histamine methyltransferase: Structural, thermal, and kinetic comparisons</article-title>
<source/>Structure
          <year>2001</year>
<volume>9</volume>
<fpage>837</fpage>
<lpage>849</lpage>
<pub-id pub-id-type="doi">10.1016/S0969-2126(01)00643-8</pub-id>
<pub-id pub-id-type="pmid">11566133</pub-id>
</element-citation>
</ref>
<ref id="B53-ijms-20-00737">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rutherford</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Parson</surname>
<given-names>W.W.</given-names>
</name>
<name>
<surname>Daggett</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>The histamine <italic>N</italic>-methyltransferase T105I polymorphism affects active site structure and dynamics</article-title>
<source/>Biochemistry
          <year>2008</year>
<volume>47</volume>
<fpage>893</fpage>
<lpage>901</lpage>
<pub-id pub-id-type="doi">10.1021/bi701737f</pub-id>
<pub-id pub-id-type="pmid">18154359</pub-id>
</element-citation>
</ref>
<ref id="B54-ijms-20-00737">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agundez</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Luengo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Herraez</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Alonso-Navarro</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jimenez-Jimenez</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Garcia-Martin</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Nonsynonymous polymorphisms of histamine-metabolising enzymes in patients with Parkinson’s disease</article-title>
<source/>Neuromolecular Med.
          <year>2008</year>
<volume>10</volume>
<fpage>10</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1007/s12017-007-8017-7</pub-id>
<pub-id pub-id-type="pmid">17985251</pub-id>
</element-citation>
</ref>
<ref id="B55-ijms-20-00737">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keeling</surname>
<given-names>B.H.</given-names>
</name>
<name>
<surname>Vilarino-Guell</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Soto-Ortolaza</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>O.A.</given-names>
</name>
<name>
<surname>Uitti</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Rajput</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wszolek</surname>
<given-names>Z.K.</given-names>
</name>
<name>
<surname>Farrer</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>Histamine <italic>N</italic>-methyltransferase Thr105Ile is not associated with Parkinson’s disease or essential tremor</article-title>
<source/>Parkinsonism Relat. Disord.
          <year>2010</year>
<volume>16</volume>
<fpage>112</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2009.08.011</pub-id>
<pub-id pub-id-type="pmid">19773194</pub-id>
</element-citation>
</ref>
<ref id="B56-ijms-20-00737">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palada</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Terzic</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mazzulli</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bwala</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hagenah</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Peterlin</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>A.Y.</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Krainc</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Histamine <italic>N</italic>-methyltransferase Thr105Ile polymorphism is associated with Parkinson’s disease</article-title>
<source/>Neurobiol. Aging
          <year>2012</year>
<volume>33</volume>
<fpage>836 e1</fpage>
<lpage>836 e3</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2011.06.015</pub-id>
</element-citation>
</ref>
<ref id="B57-ijms-20-00737">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Association of histamine <italic>N</italic>-methyltransferase Thr105Ile polymorphism with Parkinson’s disease and schizophrenia in Han Chinese: A case-control study</article-title>
<source/>PLoS ONE
          <year>2015</year>
<volume>10</volume>
<elocation-id>e0119692</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0119692</pub-id>
<pub-id pub-id-type="pmid">25768024</pub-id>
</element-citation>
</ref>
<ref id="B58-ijms-20-00737">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jimenez-Jimenez</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Alonso-Navarro</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Garcia-Martin</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Agundez</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Thr105Ile (rs11558538) polymorphism in the histamine <italic>N</italic>-methyltransferase (HNMT) gene and risk for Parkinson disease: A PRISMA-compliant systematic review and meta-analysis</article-title>
<source/>Medicine (Baltimore)
          <year>2016</year>
<volume>95</volume>
<fpage>e4147</fpage>
<pub-id pub-id-type="doi">10.1097/MD.0000000000004147</pub-id>
<pub-id pub-id-type="pmid">27399132</pub-id>
</element-citation>
</ref>
<ref id="B59-ijms-20-00737">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stevenson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sonuga-Barke</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>McCann</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Grimshaw</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Rose-Zerilli</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Holloway</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Warner</surname>
<given-names>J.O.</given-names>
</name>
</person-group>
<article-title>The role of histamine degradation gene polymorphisms in moderating the effects of food additives on children’s ADHD symptoms</article-title>
<source/>Am. J. Psychiatry.
          <year>2010</year>
<volume>167</volume>
<fpage>1108</fpage>
<lpage>1115</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.2010.09101529</pub-id>
<pub-id pub-id-type="pmid">20551163</pub-id>
</element-citation>
</ref>
<ref id="B60-ijms-20-00737">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meza-Velazquez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lopez-Marquez</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Espinosa-Padilla</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rivera-Guillen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Avila-Hernandez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rosales-Gonzalez</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Association of diamine oxidase and histamine <italic>N</italic>-methyltransferase polymorphisms with presence of migraine in a group of Mexican mothers of children with allergies</article-title>
<source/>Neurologia
          <year>2017</year>
<volume>32</volume>
<fpage>500</fpage>
<lpage>507</lpage>
<pub-id pub-id-type="doi">10.1016/j.nrleng.2016.02.012</pub-id>
<pub-id pub-id-type="pmid">27130307</pub-id>
</element-citation>
</ref>
<ref id="B61-ijms-20-00737">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marasovic-Susnjara</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Palada</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Marinovic-Terzic</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Mimica</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Marin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Muck-Seler</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mustapic</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Presecki</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pivac</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Folnegovic-Smalc</surname>
<given-names>V.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>No association between histamine <italic>N</italic>-methyltransferase functional polymorphism Thr105Ile and Alzheimer’s disease</article-title>
<source/>Neurosci. Lett.
          <year>2011</year>
<volume>489</volume>
<fpage>119</fpage>
<lpage>121</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2010.11.078</pub-id>
<pub-id pub-id-type="pmid">21138759</pub-id>
</element-citation>
</ref>
<ref id="B62-ijms-20-00737">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ou</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Shang</surname>
<given-names>H.F.</given-names>
</name>
</person-group>
<article-title>Determining the Effect of the HNMT, STK39, and NMD3 Polymorphisms on the Incidence of Parkinson’s Disease, Amyotrophic Lateral Sclerosis, and Multiple System Atrophy in Chinese Populations</article-title>
<source/>J. Mol. Neurosci.
          <year>2018</year>
<volume>64</volume>
<fpage>574</fpage>
<lpage>580</lpage>
<pub-id pub-id-type="doi">10.1007/s12031-018-1048-8</pub-id>
<pub-id pub-id-type="pmid">29564728</pub-id>
</element-citation>
</ref>
<ref id="B63-ijms-20-00737">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Martin</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Benito-Leon</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Calleja</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Diaz-Sanchez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pisa</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Alonso-Navarro</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ayuso-Peralta</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Torrecilla</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Agundez</surname>
<given-names>J.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Histamine-<italic>N</italic>-methyl transferase polymorphism and risk for multiple sclerosis</article-title>
<source/>Eur. J. Neurol.
          <year>2010</year>
<volume>17</volume>
<fpage>335</fpage>
<lpage>338</lpage>
<pub-id pub-id-type="doi">10.1111/j.1468-1331.2009.02720.x</pub-id>
<pub-id pub-id-type="pmid">19538200</pub-id>
</element-citation>
</ref>
<ref id="B64-ijms-20-00737">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jimenez-Jimenez</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Garcia-Martin</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Alonso-Navarro</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zurdo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Turpin-Fenoll</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Millan-Pascual</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Adeva-Bartolome</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Cubo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Navacerrada</surname>
<given-names>F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Thr105Ile (rs11558538) polymorphism in the histamine-1-methyl-transferase (HNMT) gene and risk for restless legs syndrome</article-title>
<source/>J. Neural. Transm. (Vienna)
          <year>2017</year>
<volume>124</volume>
<fpage>285</fpage>
<lpage>291</lpage>
<pub-id pub-id-type="doi">10.1007/s00702-016-1645-z</pub-id>
<pub-id pub-id-type="pmid">27837280</pub-id>
</element-citation>
</ref>
<ref id="B65-ijms-20-00737">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reuter</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jeste</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hennig</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Goldman</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Enoch</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Oroszi</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Association of THR105Ile, a functional polymorphism of histamine <italic>N</italic>-methyltransferase (HNMT), with alcoholism in German Caucasians</article-title>
<source/>Drug Alcohol Depend.
          <year>2007</year>
<volume>87</volume>
<fpage>69</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2006.08.006</pub-id>
<pub-id pub-id-type="pmid">16950574</pub-id>
</element-citation>
</ref>
<ref id="B66-ijms-20-00737">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oroszi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Enoch</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Chun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Virkkunen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Goldman</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Thr105Ile, a functional polymorphism of histamine <italic>N</italic>-methyltransferase, is associated with alcoholism in two independent populations</article-title>
<source/>Alcohol Clin. Exp. Res.
          <year>2005</year>
<volume>29</volume>
<fpage>303</fpage>
<lpage>309</lpage>
<pub-id pub-id-type="doi">10.1097/01.ALC.0000156128.28257.2E</pub-id>
<pub-id pub-id-type="pmid">15770103</pub-id>
</element-citation>
</ref>
<ref id="B67-ijms-20-00737">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>Y.M.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>B.Y.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>Y.M.</given-names>
</name>
<name>
<surname>Hur</surname>
<given-names>G.Y.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>H.S.</given-names>
</name>
</person-group>
<article-title>Histamine <italic>N</italic>-methyltransferase 939A&gt;G polymorphism affects mRNA stability in patients with acetylsalicylic acid-intolerant chronic urticaria</article-title>
<source/>Allergy
          <year>2009</year>
<volume>64</volume>
<fpage>213</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1111/j.1398-9995.2008.01795.x</pub-id>
<pub-id pub-id-type="pmid">19178400</pub-id>
</element-citation>
</ref>
<ref id="B68-ijms-20-00737">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kellermayer</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Polgar</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Pal</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Banati</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Maasz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kisfali</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hosszu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Juhasz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>H.B.</given-names>
</name>
<name>
<surname>Tordai</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of myasthenia gravis with polymorphisms in the gene of histamine <italic>N</italic>-methyltransferase</article-title>
<source/>Hum. Immunol.
          <year>2013</year>
<volume>74</volume>
<fpage>1701</fpage>
<lpage>1704</lpage>
<pub-id pub-id-type="doi">10.1016/j.humimm.2013.07.016</pub-id>
<pub-id pub-id-type="pmid">23932992</pub-id>
</element-citation>
</ref>
<ref id="B69-ijms-20-00737">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heidari</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tongsook</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Najafipour</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Musante</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Vasli</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Garshasbi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mittal</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>McNaughton</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Sritharan</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in the histamine <italic>N</italic>-methyltransferase gene, HNMT, are associated with nonsyndromic autosomal recessive intellectual disability</article-title>
<source/>Hum. Mol. Genet.
          <year>2015</year>
<volume>24</volume>
<fpage>5697</fpage>
<lpage>5710</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddv286</pub-id>
<pub-id pub-id-type="pmid">26206890</pub-id>
</element-citation>
</ref>
<ref id="B70-ijms-20-00737">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tongsook</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Niederhauser</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kronegger</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Straganz</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Macheroux</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Leucine 208 in human histamine <italic>N</italic>-methyltransferase emerges as a hotspot for protein stability rationalizing the role of the L208P variant in intellectual disability</article-title>
<source/>Biochim. Biophys. Acta Mol. Basis Dis.
          <year>2017</year>
<volume>1863</volume>
<fpage>188</fpage>
<lpage>199</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2016.10.005</pub-id>
<pub-id pub-id-type="pmid">27769936</pub-id>
</element-citation>
</ref>
<ref id="B71-ijms-20-00737">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Wamelen</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Aziz</surname>
<given-names>N.A.</given-names>
</name>
<name>
<surname>Anink</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Roos</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Swaab</surname>
<given-names>D.F.</given-names>
</name>
</person-group>
<article-title>Functional increase of brain histaminergic signaling in Huntington’s disease</article-title>
<source/>Brain Pathol.
          <year>2011</year>
<volume>21</volume>
<fpage>419</fpage>
<lpage>427</lpage>
<pub-id pub-id-type="doi">10.1111/j.1750-3639.2010.00465.x</pub-id>
<pub-id pub-id-type="pmid">21106039</pub-id>
</element-citation>
</ref>
<ref id="B72-ijms-20-00737">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bossers</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Luchetti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Balesar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lethbridge</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Chazot</surname>
<given-names>P.L.</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Swaab</surname>
<given-names>D.F.</given-names>
</name>
</person-group>
<article-title>Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson’s patients: A postmortem study</article-title>
<source/>Neurobiol. Aging
          <year>2012</year>
<volume>33</volume>
<fpage>1488 e1</fpage>
<lpage>1488 e13</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2011.12.026</pub-id>
<pub-id pub-id-type="pmid">22284987</pub-id>
</element-citation>
</ref>
<ref id="B73-ijms-20-00737">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Krapfenbauer</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Cheon</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Fountoulakis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cairns</surname>
<given-names>N.J.</given-names>
</name>
<name>
<surname>Lubec</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Human brain cytosolic histamine-<italic>N</italic>-methyltransferase is decreased in Down syndrome and increased in Pick’s disease</article-title>
<source/>Neurosci. Lett.
          <year>2002</year>
<volume>321</volume>
<fpage>169</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="doi">10.1016/S0304-3940(02)00051-4</pub-id>
<pub-id pub-id-type="pmid">11880199</pub-id>
</element-citation>
</ref>
<ref id="B74-ijms-20-00737">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bossers</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Unmehopa</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Swaab</surname>
<given-names>D.F.</given-names>
</name>
</person-group>
<article-title>Alterations in the histaminergic system in Alzheimer’s disease: A postmortem study</article-title>
<source/>Neurobiol. Aging
          <year>2012</year>
<volume>33</volume>
<fpage>2585</fpage>
<lpage>2598</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2011.12.026</pub-id>
<pub-id pub-id-type="pmid">22284987</pub-id>
</element-citation>
</ref>
<ref id="B75-ijms-20-00737">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>X.R.</given-names>
</name>
<name>
<surname>Balesar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Swaab</surname>
<given-names>D.F.</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>A.M.</given-names>
</name>
</person-group>
<article-title>Unaltered histaminergic system in depression: A postmortem study</article-title>
<source/>J. Affect. Disord.
          <year>2013</year>
<volume>146</volume>
<fpage>220</fpage>
<lpage>223</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2012.09.008</pub-id>
<pub-id pub-id-type="pmid">23026128</pub-id>
</element-citation>
</ref>
<ref id="B76-ijms-20-00737">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duch</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Bowers</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Nichol</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>Elevation of brain histamine levels by diaminopyrimidine inhibitors of histamine <italic>N</italic>-methyl transferase</article-title>
<source/>Biochem. Pharmacol.
          <year>1978</year>
<volume>27</volume>
<fpage>1507</fpage>
<lpage>1509</lpage>
<pub-id pub-id-type="doi">10.1016/0006-2952(78)90109-0</pub-id>
<pub-id pub-id-type="pmid">697892</pub-id>
</element-citation>
</ref>
<ref id="B77-ijms-20-00737">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duch</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Edelstein</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Nichol</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>Inhibition of histamine-metabolizing enzymes and elevation of histamine levels in tissues by lipid-soluble anticancer folate antagonists</article-title>
<source/>Mol. Pharmacol.
          <year>1980</year>
<volume>18</volume>
<fpage>100</fpage>
<lpage>104</lpage>
<pub-id pub-id-type="pmid">6774226</pub-id>
</element-citation>
</ref>
<ref id="B78-ijms-20-00737">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hough</surname>
<given-names>L.B.</given-names>
</name>
<name>
<surname>Khandelwal</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Inhibition of brain histamine metabolism by metoprine</article-title>
<source/>Biochem. Pharmacol.
          <year>1986</year>
<volume>35</volume>
<fpage>307</fpage>
<lpage>310</lpage>
<pub-id pub-id-type="doi">10.1016/0006-2952(86)90530-7</pub-id>
<pub-id pub-id-type="pmid">3942601</pub-id>
</element-citation>
</ref>
<ref id="B79-ijms-20-00737">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malmberg-Aiello</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lamberti</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ghelardini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Giotti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bartolini</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Role of histamine in rodent antinociception</article-title>
<source/>Br. J. Pharmacol.
          <year>1994</year>
<volume>111</volume>
<fpage>1269</fpage>
<lpage>1279</lpage>
<pub-id pub-id-type="doi">10.1111/j.1476-5381.1994.tb14883.x</pub-id>
<pub-id pub-id-type="pmid">8032614</pub-id>
</element-citation>
</ref>
<ref id="B80-ijms-20-00737">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecklin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tuomisto</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Inhibition of histamine catabolism suppresses fat intake but not the intake of carbohydrates and protein</article-title>
<source/>Inflamm. Res.
          <year>2002</year>
<volume>51</volume>
<fpage>S53</fpage>
<lpage>S54</lpage>
<pub-id pub-id-type="pmid">12013408</pub-id>
</element-citation>
</ref>
<ref id="B81-ijms-20-00737">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishibori</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Itoh</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Oishi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Saeki</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Mechanism of the central hyperglycemic action of histamine in mice</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>1987</year>
<volume>241</volume>
<fpage>582</fpage>
<lpage>586</lpage>
<pub-id pub-id-type="pmid">3572814</pub-id>
</element-citation>
</ref>
<ref id="B82-ijms-20-00737">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malmberg-Aiello</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ipponi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bartolini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schunack</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Antiamnesic effect of metoprine and of selective histamine H(1) receptor agonists in a modified mouse passive avoidance test</article-title>
<source/>Neurosci. Lett.
          <year>2000</year>
<volume>288</volume>
<fpage>1</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="doi">10.1016/S0304-3940(00)01176-9</pub-id>
<pub-id pub-id-type="pmid">10869801</pub-id>
</element-citation>
</ref>
<ref id="B83-ijms-20-00737">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yawata</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Murashima</surname>
<given-names>Y.L.</given-names>
</name>
<name>
<surname>Nakano</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Role of histaminergic neurons in development of epileptic seizures in EL mice</article-title>
<source/>Brain Res. Mol. Brain Res.
          <year>2004</year>
<volume>132</volume>
<fpage>13</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1016/j.molbrainres.2004.08.019</pub-id>
<pub-id pub-id-type="pmid">15548424</pub-id>
</element-citation>
</ref>
<ref id="B84-ijms-20-00737">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamei</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Involvement of central histamine in amygdaloid kindled seizures in rats</article-title>
<source/>Behav. Brain Res.
          <year>2001</year>
<volume>124</volume>
<fpage>243</fpage>
<lpage>250</lpage>
<pub-id pub-id-type="doi">10.1016/S0166-4328(01)00218-2</pub-id>
<pub-id pub-id-type="pmid">11640977</pub-id>
</element-citation>
</ref>
<ref id="B85-ijms-20-00737">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yokoyama</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Onodera</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Maeyama</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yanai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Iinuma</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tuomisto</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Histamine levels and clonic convulsions of electrically-induced seizure in mice: The effects of alpha-fluoromethylhistidine and metoprine</article-title>
<source/>Naunyn Schmiedebergs Arch. Pharmacol.
          <year>1992</year>
<volume>346</volume>
<fpage>40</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="doi">10.1007/BF00167568</pub-id>
<pub-id pub-id-type="pmid">1407004</pub-id>
</element-citation>
</ref>
<ref id="B86-ijms-20-00737">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kitanaka</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kitanaka</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>F.S.</given-names>
</name>
<name>
<surname>Uhl</surname>
<given-names>G.R.</given-names>
</name>
<name>
<surname>Takemura</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Brain Histamine <italic>N</italic>-Methyltransferase As a Possible Target of Treatment for Methamphetamine Overdose</article-title>
<source/>Drug Target Insights
          <year>2016</year>
<volume>10</volume>
<fpage>1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.4137/DTI.S38342</pub-id>
</element-citation>
</ref>
<ref id="B87-ijms-20-00737">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cavallito</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Nichol</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Brenckman</surname>
<given-names>W.D.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Deangelis</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Stickney</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Simmons</surname>
<given-names>W.S.</given-names>
</name>
<name>
<surname>Sigel</surname>
<given-names>C.W.</given-names>
</name>
</person-group>
<article-title>Lipid-soluble inhibitors of dihydrofolate reductase. I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man</article-title>
<source/>Drug Metab. Dispos.
          <year>1978</year>
<volume>6</volume>
<fpage>329</fpage>
<lpage>337</lpage>
<pub-id pub-id-type="pmid">26555</pub-id>
</element-citation>
</ref>
<ref id="B88-ijms-20-00737">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamrell</surname>
<given-names>M.R.</given-names>
</name>
</person-group>
<article-title>Inhibition of dihydrofolate reductase and cell growth by antifolates in a methotrexate-resistant cell line</article-title>
<source/>Oncology
          <year>1984</year>
<volume>41</volume>
<fpage>343</fpage>
<lpage>348</lpage>
<pub-id pub-id-type="doi">10.1159/000225851</pub-id>
<pub-id pub-id-type="pmid">6540852</pub-id>
</element-citation>
</ref>
<ref id="B89-ijms-20-00737">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beaven</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Shaff</surname>
<given-names>R.E.</given-names>
</name>
</person-group>
<article-title>New inhibitors of histamine-<italic>N</italic>-methyltransferase</article-title>
<source/>Biochem. Pharmacol.
          <year>1979</year>
<volume>28</volume>
<fpage>183</fpage>
<lpage>188</lpage>
<pub-id pub-id-type="doi">10.1016/0006-2952(79)90500-8</pub-id>
<pub-id pub-id-type="pmid">34400</pub-id>
</element-citation>
</ref>
<ref id="B90-ijms-20-00737">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Sakai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jouvet</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Evidence for histaminergic arousal mechanisms in the hypothalamus of cat</article-title>
<source/>Neuropharmacology
          <year>1988</year>
<volume>27</volume>
<fpage>111</fpage>
<lpage>122</lpage>
<pub-id pub-id-type="doi">10.1016/0028-3908(88)90159-1</pub-id>
<pub-id pub-id-type="pmid">2965315</pub-id>
</element-citation>
</ref>
<ref id="B91-ijms-20-00737">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malmberg-Aiello</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lamberti</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ipponi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hanninen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ghelardini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bartolini</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Effects of two histamine-<italic>N</italic>-methyltransferase inhibitors, SKF 91488 and BW 301 U, in rodent antinociception</article-title>
<source/>Naunyn Schmiedebergs Arch. Pharmacol.
          <year>1997</year>
<volume>355</volume>
<fpage>354</fpage>
<lpage>360</lpage>
<pub-id pub-id-type="doi">10.1007/PL00004954</pub-id>
<pub-id pub-id-type="pmid">9089666</pub-id>
</element-citation>
</ref>
<ref id="B92-ijms-20-00737">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fiorenza</surname>
<given-names>N.G.</given-names>
</name>
<name>
<surname>Rosa</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Izquierdo</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Myskiw</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Modulation of the extinction of two different fear-motivated tasks in three distinct brain areas</article-title>
<source/>Behav. Brain Res.
          <year>2012</year>
<volume>232</volume>
<fpage>210</fpage>
<lpage>216</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2012.04.015</pub-id>
<pub-id pub-id-type="pmid">22525015</pub-id>
</element-citation>
</ref>
<ref id="B93-ijms-20-00737">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horton</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Sawada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nishibori</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Structural basis for inhibition of histamine <italic>N</italic>-methyltransferase by diverse drugs</article-title>
<source/>J. Mol. Biol.
          <year>2005</year>
<volume>353</volume>
<fpage>334</fpage>
<lpage>344</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmb.2005.08.040</pub-id>
<pub-id pub-id-type="pmid">16168438</pub-id>
</element-citation>
</ref>
<ref id="B94-ijms-20-00737">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tachibana</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Taniguchi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Imamura</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fujiwara</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Effects of drugs on the activity of histamine-<italic>N</italic>-methyltransferase from guinea pig skin</article-title>
<source/>Biochem. Pharmacol.
          <year>1988</year>
<volume>37</volume>
<fpage>2872</fpage>
<lpage>2876</lpage>
<pub-id pub-id-type="pmid">2899431</pub-id>
</element-citation>
</ref>
<ref id="B95-ijms-20-00737">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cumming</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Reiner</surname>
<given-names>P.B.</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>S.R.</given-names>
</name>
</person-group>
<article-title>Inhibition of rat brain histamine-<italic>N</italic>-methyltransferase by 9-amino-1,2,3,4-tetrahydroacridine (THA)</article-title>
<source/>Biochem. Pharmacol.
          <year>1990</year>
<volume>40</volume>
<fpage>1345</fpage>
<lpage>1350</lpage>
<pub-id pub-id-type="doi">10.1016/0006-2952(90)90402-7</pub-id>
<pub-id pub-id-type="pmid">2403387</pub-id>
</element-citation>
</ref>
<ref id="B96-ijms-20-00737">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nomura</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mizuta</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Norimoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Masuda</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Miura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kubo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kojima</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ashizuka</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Matsukawa</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Baraki</surname>
<given-names>Z.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Central Histamine Boosts Perirhinal Cortex Activity and Restores Forgotten Object Memories</article-title>
<source/>Biol. Psychiatry
          <year>2018</year>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2018.11.009</pub-id>
</element-citation>
</ref>
<ref id="B97-ijms-20-00737">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sasahara</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Fujimura</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nozawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Furuhata</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>The effect of histidine on mental fatigue and cognitive performance in subjects with high fatigue and sleep disruption scores</article-title>
<source/>Physiol. Behav.
          <year>2015</year>
<volume>147</volume>
<fpage>238</fpage>
<lpage>244</lpage>
<pub-id pub-id-type="doi">10.1016/j.physbeh.2015.04.042</pub-id>
<pub-id pub-id-type="pmid">25921948</pub-id>
</element-citation>
</ref>
<ref id="B98-ijms-20-00737">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malmlof</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zaragoza</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Golozoubova</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Refsgaard</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Cremers</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Raun</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wulff</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Johansen</surname>
<given-names>P.B.</given-names>
</name>
<name>
<surname>Westerink</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Rimvall</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Influence of a selective histamine H3 receptor antagonist on hypothalamic neural activity, food intake and body weight</article-title>
<source/>Int. J. Obes. (Lond.)
          <year>2005</year>
<volume>29</volume>
<fpage>1402</fpage>
<lpage>1412</lpage>
<pub-id pub-id-type="doi">10.1038/sj.ijo.0803036</pub-id>
<pub-id pub-id-type="pmid">16151415</pub-id>
</element-citation>
</ref>
<ref id="B99-ijms-20-00737">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morisset</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Traiffort</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Arrang</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Changes in histamine H3 receptor responsiveness in mouse brain</article-title>
<source/>J. Neurochem.
          <year>2000</year>
<volume>74</volume>
<fpage>339</fpage>
<lpage>346</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.2000.0740339.x</pub-id>
<pub-id pub-id-type="pmid">10617138</pub-id>
</element-citation>
</ref>
<ref id="B100-ijms-20-00737">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Martin</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Garcia-Menaya</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sanchez</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rosendo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Agundez</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Polymorphisms of histamine-metabolizing enzymes and clinical manifestations of asthma and allergic rhinitis</article-title>
<source/>Clin. Exp. Allergy
          <year>2007</year>
<volume>37</volume>
<fpage>1175</fpage>
<lpage>1182</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2222.2007.02769.x</pub-id>
<pub-id pub-id-type="pmid">17651147</pub-id>
</element-citation>
</ref>
<ref id="B101-ijms-20-00737">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>T.P.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Lack of association of histamine-<italic>N</italic>-methyltransferase (HNMT) polymorphisms with asthma in the Indian population</article-title>
<source/>J. Hum. Genet.
          <year>2005</year>
<volume>50</volume>
<fpage>611</fpage>
<lpage>617</lpage>
<pub-id pub-id-type="doi">10.1007/s10038-005-0302-4</pub-id>
<pub-id pub-id-type="pmid">16205835</pub-id>
</element-citation>
</ref>
<ref id="B102-ijms-20-00737">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deindl</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Peri-Jerkan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Deichmann</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Niggemann</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lau</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sommerfeld</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sengler</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wahn</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Nickel</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>No association of histamine-<italic>N</italic>-methyltransferase polymorphism with asthma or bronchial hyperresponsiveness in two German pediatric populations</article-title>
<source/>Pediatr. Allergy Immunol.
          <year>2005</year>
<volume>16</volume>
<fpage>40</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="doi">10.1111/j.1399-3038.2005.00218.x</pub-id>
<pub-id pub-id-type="pmid">15693910</pub-id>
</element-citation>
</ref>
<ref id="B103-ijms-20-00737">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szczepankiewicz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Breborowicz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sobkowiak</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Popiel</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Polymorphisms of two histamine-metabolizing enzymes genes and childhood allergic asthma: A case control study</article-title>
<source/>Clin. Mol. Allergy
          <year>2010</year>
<volume>8</volume>
<fpage>14</fpage>
<pub-id pub-id-type="doi">10.1186/1476-7961-8-14</pub-id>
<pub-id pub-id-type="pmid">21040557</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="ijms-20-00737-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Neurotransmission and termination of histaminergic nervous system. Histidine decarboxylase (Hdc) synthesises histamine from histidine. Histamine is stored in synaptic vesicles via vesicular monoamine transporter 2 (Vmat2). Upon stimulation, histamine is released to extraneuronal spaces. Histamine exerts its effects through interactions with postsynaptic histamine h1 receptor (H<sub>1</sub>R) and H<sub>2</sub>R, and presynaptic H<sub>3</sub>R. Extracellular histamine is transported via organic cation transporter 3 (Oct3) and plasma membrane monoamine transporter (Pmat). Finally, histamine is metabolised by histamine <italic>N</italic>-methyltransferase (Hnmt) [<xref ref-type="bibr" rid="B19-ijms-20-00737">19</xref>,<xref ref-type="bibr" rid="B32-ijms-20-00737">32</xref>]. Although previous studies have shown the importance of astrocytes for histamine clearance in the CNS [<xref ref-type="bibr" rid="B18-ijms-20-00737">18</xref>], several reports suggest the involvement of neurons in histamine clearance [<xref ref-type="bibr" rid="B33-ijms-20-00737">33</xref>,<xref ref-type="bibr" rid="B34-ijms-20-00737">34</xref>].</p>
</caption>
<graphic xlink:href="ijms-20-00737-g001"></graphic>
</fig>
<fig id="ijms-20-00737-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Enzymatic activity of histamine <italic>N</italic>-methyltransferase. Histamine <italic>N</italic>-methyltransferase catalyses the transfer of a methyl group from S-adenosyl-<sc>l</sc>-methionine to histamine, yielding <italic>N<sup>τ</sup></italic>-methylhistamine and S-adenosyl-<sc>l</sc>-homocysteine.</p>
</caption>
<graphic xlink:href="ijms-20-00737-g002"></graphic>
</fig>
<fig id="ijms-20-00737-f003" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>Structures of HNMT inhibitors. Structures of typical HNMT inhibitors amodiaquine, tacrine, etoprine, metoprine, chloroquine, quinacrine, dimaprit, and SKF91488 are depicted.</p>
</caption>
<graphic xlink:href="ijms-20-00737-g003"></graphic>
</fig>
<table-wrap id="ijms-20-00737-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-20-00737-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Basic data of human, mouse, rat, and guinea pig histamine <italic>N</italic>-methyltransferase (HNMT).</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="2" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Human [<xref ref-type="bibr" rid="B39-ijms-20-00737">39</xref>,<xref ref-type="bibr" rid="B48-ijms-20-00737">48</xref>]</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Mouse [<xref ref-type="bibr" rid="B49-ijms-20-00737">49</xref>]</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Rat [<xref ref-type="bibr" rid="B50-ijms-20-00737">50</xref>]</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Guinea pig [<xref ref-type="bibr" rid="B51-ijms-20-00737">51</xref>]</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">Cloning year</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1994</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2001</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1992</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2001</td>
</tr>
<tr>
<td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">Chromosome</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2q22.1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2A3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3p13</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N.D.</td>
</tr>
<tr>
<td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">Amino acid</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">292 aa</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">295 aa</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">292 aa</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">295 aa</td>
</tr>
<tr>
<td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">Homology *</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">83%</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">83%</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">81%</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">K<sub>m</sub> (µM)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Histamine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">13–20</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">5.3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">7.1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N.D.</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SAM</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2.0–6.2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">5.8</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">6.3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N.D.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>* Homology to human HNMT protein; aa—amino acids; K<sub>m</sub>—Michaelis constant; N.D.—not determined; SAM—S-adenosyl-L-methionine.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="ijms-20-00737-t002" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-20-00737-t002_Table 2</object-id>
<label>Table 2</label>
<caption>
<p>Human <italic>HNMT</italic> mutations and brain diseases.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Authors</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Year</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">SNP</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Enzymatic Activity</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Disease</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Association</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Note</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Jimenez-Jimenez et al. [<xref ref-type="bibr" rid="B58-ijms-20-00737">58</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2016</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">C314T<break></break>(Thr105Ile)<break></break>(rs11558538)<break></break>T allele carrier</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decreased</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Parkinson’s disease (PD)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Diagnostic OR 0.61</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Caucasians and Asians</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Yang et al. [<xref ref-type="bibr" rid="B57-ijms-20-00737">57</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2015</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">C314T<break></break>(Thr105Ile)<break></break>(rs11558538)<break></break>CT hetero allele</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decreased</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">PD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">OR 0.53</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Han Chinese</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Palada et al. [<xref ref-type="bibr" rid="B56-ijms-20-00737">56</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2012</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">C314T<break></break>(Thr105Ile)<break></break>(rs11558538)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decreased</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">PD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Thr105 frequency was associated with PD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Caucasians</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Yang et al. [<xref ref-type="bibr" rid="B57-ijms-20-00737">57</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2015</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">C314T<break></break>(Thr105Ile)<break></break>(rs11558538)<break></break>CT hetero allele</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decreased</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Schizophrenia</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">OR 0.499</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Han Chinese</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Stevenson et al. [<xref ref-type="bibr" rid="B59-ijms-20-00737">59</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2010</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">C314T<break></break>(Thr105Ile)<break></break>(rs11558538)<break></break>T allele</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decreased</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ADHD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decreased hyperactivity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Food additives stimulation</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Stevenson et al. [<xref ref-type="bibr" rid="B59-ijms-20-00737">59</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2010</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A939G (3′-UTR)<break></break>(rs1050891)<break></break>G allele</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased (mRNA stability)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ADHD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decreased hyperactivity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Food additives stimulation</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Meza-Velazquez et al. [<xref ref-type="bibr" rid="B60-ijms-20-00737">60</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2017</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">C314T<break></break>(Thr105Ile)<break></break>(rs11558538)<break></break>CT hetero allele</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decreased</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Migraine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">OR 37.10</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Migraine-related disability Grade IV</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Kellermayer et al. [<xref ref-type="bibr" rid="B68-ijms-20-00737">68</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2017</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A939G<break></break>(3′-UTR)<break></break>(rs1050891)<break></break>G allele</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased (mRNA stability)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Myasthenia gravis (MG)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">OR 0.52</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Anti-Titin positive MG</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Heidari et al. [<xref ref-type="bibr" rid="B69-ijms-20-00737">69</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2015</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">G179A<break></break>(Gly60Asp)<break></break>(rs758252808)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decreased</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Intellectual disability (AR)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Low IQ</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Turkish</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Heidari et al. [<xref ref-type="bibr" rid="B69-ijms-20-00737">69</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2015</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">T632C<break></break>(Leu208Pro)<break></break>(rs745756308)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decreased</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Intellectual disability (AR)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Low IQ</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Kurdish</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Marasovic-Susnjara et al. [<xref ref-type="bibr" rid="B61-ijms-20-00737">61</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2011</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">C314T<break></break>(Thr105Ile)<break></break>(rs11558538)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decreased</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Alzheimer’s disease</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">No association</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Chen et al. [<xref ref-type="bibr" rid="B62-ijms-20-00737">62</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2018</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">C314<break></break>(Thr105Ile)<break></break>(rs11558538)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decreased</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Amyotrophic Lateral Sclerosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">No association</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reuter et al. [<xref ref-type="bibr" rid="B65-ijms-20-00737">65</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2007</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">C314T<break></break>(Thr105Ile)<break></break>(rs11558538)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decreased</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Alcoholism</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">No association</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">German Caucasians</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Oroszi et al. [<xref ref-type="bibr" rid="B66-ijms-20-00737">66</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2006</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">C314T<break></break>(Thr105Ile)<break></break>(rs11558538)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decreased</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Alcoholism</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Thr105 frequency was associated with alcoholism.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Finnish Caucasians, Plains Indians</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gracia-Martin et al. [<xref ref-type="bibr" rid="B63-ijms-20-00737">63</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2010</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">C314T<break></break>(Thr105Ile)<break></break>(rs11558538)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decreased</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Multiple sclerosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">No association</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Jimenez-Jimenez et al. [<xref ref-type="bibr" rid="B64-ijms-20-00737">64</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2016</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">C314T<break></break>(Thr105Ile)<break></break>(rs11558538)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Decreased</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Restless legs syndrome (RLS)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">No association<break></break>(TT allele might be a risk factor for early onset of RLS)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>PD–Parkinson’s disease; OR–Odds ratio; ADHD–Attention deficit hyperactivity disorder; IQ–Intelligence quotient; SNP—single nucleotide polymorphism.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="ijms-20-00737-t003" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-20-00737-t003_Table 3</object-id>
<label>Table 3</label>
<caption>
<p>Characteristics of HNMT inhibitors.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Inhibitors</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">M.W.</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">IC<sub>50</sub> or K<sub>i</sub></th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Inhibition Pattern</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Note</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Amodiaquine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">355.86</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">K<sub>i</sub> 18.6 nM (recombinant hHNMT) [<xref ref-type="bibr" rid="B93-ijms-20-00737">93</xref>]<break></break>IC<sub>50</sub> 400 nM (recombinant hHNMT) [<xref ref-type="bibr" rid="B39-ijms-20-00737">39</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mixed</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">An antimalarial drug</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Chloroquine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">319.88</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">IC<sub>50</sub> 600 nM (guinea pig skin) [<xref ref-type="bibr" rid="B94-ijms-20-00737">94</xref>]<break></break>IC<sub>50</sub> 12.6, 22.0 19.0 and 21.7 µM (human liver, renal cortex, brain and colon) [<xref ref-type="bibr" rid="B44-ijms-20-00737">44</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Competitive to histamine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">An antimalarial drug</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Dimaprit</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">161.27</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">K<sub>i</sub> 8 µM (rat kidney) [<xref ref-type="bibr" rid="B89-ijms-20-00737">89</xref>]<break></break>Ki 7–9 µM (guinea pig brain) [<xref ref-type="bibr" rid="B89-ijms-20-00737">89</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Noncompetitive to histamine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">H<sub>2</sub>R agonist</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Etoprine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">283.16</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">K<sub>i</sub> 760 nM (rat brain) [<xref ref-type="bibr" rid="B76-ijms-20-00737">76</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N.D.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Dihydrofolate reductase inhibitor</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Metoprine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">269.13</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">K<sub>i</sub> 100 nM (rat brain) [<xref ref-type="bibr" rid="B76-ijms-20-00737">76</xref>]<break></break>K<sub>i</sub> 91 nM (recombinant hHNMT) [<xref ref-type="bibr" rid="B93-ijms-20-00737">93</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Competitive to histamine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Dihydrofolate reductase inhibitor</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Quinacrine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">399.96</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">IC<sub>50</sub> 160 nM (guinea pig skin) [<xref ref-type="bibr" rid="B94-ijms-20-00737">94</xref>]<break></break>K<sub>i</sub> 450 nM (recombinant hHNMT) [<xref ref-type="bibr" rid="B52-ijms-20-00737">52</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Competitive to histamine </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">An antimalarial drug</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SKF91488</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">175.29</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">K<sub>i</sub> 0.9–1.6 µM (rat kidney) [<xref ref-type="bibr" rid="B89-ijms-20-00737">89</xref>]<break></break>K<sub>i</sub> 1.85 µM (recombinant rat HNMT) [<xref ref-type="bibr" rid="B50-ijms-20-00737">50</xref>]<break></break>K<sub>i</sub> 3 µM (guinea pig brain) [<xref ref-type="bibr" rid="B89-ijms-20-00737">89</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Noncompetitive to histamine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Poor BBB permeability</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Tacrine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">198.27</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">K<sub>i</sub> 38.2 nM (recombinant hHNMT) [<xref ref-type="bibr" rid="B93-ijms-20-00737">93</xref>]<break></break>K<sub>i</sub> 35 nM (rat kidney) [<xref ref-type="bibr" rid="B95-ijms-20-00737">95</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Competitive to histamine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Acetylcholinesterase inhibitor</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>IC<sub>50</sub>—half maximal inhibitory concentration; K<sub>i</sub>—inhibitory constant; M.W.—molecular weight; N.D.—not determined.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>